In a report released today, Charles Duncan from Cantor Fitzgerald reiterated a Buy rating on Denali Therapeutics Inc (DNLI), with a price target of $25. The company’s shares closed yesterday at $20.23.
Duncan wrote:
“. We reiterate our Overweight rating and 12-month PT of $25/share of DNLI after attending Denali’s R&D Day. We believe the company is approaching neurodegenerative diseases through rigorous therapeutic discovery and development, and we expect increasingly visible pipeline progress will enhance investor conviction over the next 12-18 months. The event provided a broad perspective on pipeline strategy that could address many of the historic challenges for neurodegenerative disease drug development. Our focus is currently on the small molecule programs for DNL201 in Parkinson’s disease (PD) and DNL747 in Alzheimer’s disease (AD), ALS, and MS, which are the most advanced programs.”
According to TipRanks.com, Duncan is a 1-star analyst with an average return of -1.2% and a 42.0% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, KalVista Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Denali Therapeutics Inc with a $27.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.79 and a one-year low of $12.32. Currently, Denali Therapeutics Inc has an average volume of 500.4K.
Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DNLI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Denali Therapeutics, Inc. engages in the development of portfolio of therapeutic candidates for neurodegenerative diseases. Its programs comprises of lysosomal function pathway, glial biology pathway, and cellular homeostasis.
